Companies /Healthcare

Legend Biotech Corp

NASDAQ: LEGN Biotechnology
$16.10
▼ $0.15 (−0.92%) today
Markets closed · 1:38am ET

24/7 Wall St. View

LEGN at a Glance

Valuation
Market cap
$3.2B
Profitability
Revenue (TTM)
$1.4B
Profit margin
0.0%
EPS (TTM)
$-0.02
Price
52-week range
$16 – $38
Street target
$40.93

Headquartered in Somerset, NJ Fiscal year ends December NASDAQ: LEGN legendbiotech.com

About Legend Biotech

Legend Biotech is a cell therapy company with more than 3,300 employees, focused on CAR-T treatments for cancer. Its commercial product is CARVYKTI (ciltacabtagene autoleucel), a one-time BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma. Legend develops and markets CARVYKTI with Johnson & Johnson (Janssen) under a collaboration and license agreement, sharing profits and costs on a 50/50 basis. CARVYKTI is available at 373 treatment sites in 20 markets. Legend also earns license revenue from a Novartis agreement covering LB2102 and other DLL-3-targeted CAR-T therapies. Its pipeline includes next-generation modalities such as in vivo CAR-T. One example is LB2501, a CD19/CD20 dual-targeting in vivo CAR-T for B-cell malignancies that recently received FDA IND clearance. The company aims to build an end-to-end cell therapy business, expanding CARVYKTI into earlier lines of therapy while advancing its pipeline. Updated

Latest Activity

LEGNLegend Biotech
Q3 2026
EPS
$0.14
est $0.01+$0.13
Revenue
$360M
est $360M-0.1%

Legend swung to operating income of $46.8 million from a $43.3 million loss a year ago, with CARVYKTI net trade sales up 36% globally. Revenue landed in line with estimates, so the upside came from cost discipline. Updated NCCN guidelines now prefer CAR-T at first relapse, opening second and third lines.

Quarterly EPS — reported vs estimate

LEGN Coverage

Frequently Asked Questions

What does Legend Biotech do?

Legend Biotech is a cell therapy company with more than 3,300 employees, focused on CAR-T treatments for cancer. Its commercial product is CARVYKTI (ciltacabtagene autoleucel), a one-time BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma.

What is the LEGN stock price target?

The Wall Street consensus 12-month price target for LEGN is $40.93. LEGN price prediction →